13.79
Schlusskurs vom Vortag:
$13.72
Offen:
$13.86
24-Stunden-Volumen:
3.82M
Relative Volume:
1.05
Marktkapitalisierung:
$43.88B
Einnahmen:
$29.96B
Nettoeinkommen (Verlust:
$957.25M
KGV:
46.63
EPS:
0.2956
Netto-Cashflow:
$4.77B
1W Leistung:
-4.67%
1M Leistung:
-8.71%
6M Leistung:
-3.60%
1J Leistung:
-3.87%
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Vergleichen Sie TAK mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.79 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
ZTS
Zoetis Inc
|
143.28 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
HLN
Haleon Plc Adr
|
9.165 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
434.04 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-03-16 | Hochstufung | BofA Securities | Neutral → Buy |
2022-07-19 | Hochstufung | Cowen | Market Perform → Outperform |
2021-10-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-04-19 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-11-01 | Eingeleitet | Cowen | Market Perform |
2019-08-15 | Herabstufung | Daiwa Securities | Outperform → Neutral |
Alle ansehen
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases - GlobeNewswire Inc.
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
5 Best High-Yield Dividend Stocks to Buy Now - The Globe and Mail
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se
Japan's Takeda weighs India for global trials to speed up drug launches - MSN
Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN
IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl
IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN
IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - inkl
Waltham biotech’s latest pharma deal valued at $2B - The Business Journals
TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World
VIS---In addition to collaborative drug discovery research with various partners, efforts to create a pipeline are being advanced. - 富途牛牛
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Stock Market Dynamics - investchronicle.com
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
The 30-day ADR trend, in yen terms, shows high values for Keyence, Kyocera Corporation Sponsored ADR, and Murata Manufacturing. - 富途牛牛
Takeda Pharma ADR earnings beat by $150.82, revenue fell short of estimates - Investing.com UK
On the 21st, ADR movements in yen terms showed high values for NISSAN MOTOR CO LTD, NINTENDO CO LTD, and Sumitomo Trust. - 富途牛牛
Why This Biotech's Dive Benefits Its Top Three Rivals - Investor's Business Daily
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector (TAK) - Seeking Alpha
Behind Takeda Pharmaceutical Co ADR’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Takeda stock rises after positive Phase 3 results for narcolepsy drug - Investing.com
Takeda stock rises after positive Phase 3 results for narcolepsy drug By Investing.com - Investing.com South Africa
Haleon PLC Sponsored ADR (NYSE:HLN) Shares Purchased by Allspring Global Investments Holdings LLC - Defense World
Nomura Holdings Inc ADR (NYSE:NMR) Shares Acquired by GAMMA Investing LLC - Defense World
Hengan International Group (OTCMKTS:HEGIY) Stock Price Up 3.7% – Time to Buy? - Defense World
Expedia Group Earns RS Rating Upgrade - inkl
GAMMAGARD LIQUID ERC, GAMMAGARD LIQUID and GAMMAGARD S/D U.S. Important Safety Information - Placera.se
Stocks With Rising Relative Price Strength: IREN - inkl
Stocks With Rising Relative Strength: Takeda Pharmaceutical ADR - Investor's Business Daily
Nano Dimension Ltd ADR’s Shares Reel: -28.07% Quarterly Revenue Decline Amid 329.06M Market Cap - investchronicle.com
MNST’s Stock Market Adventure: 19.08% YTD Growth Amidst Volatility - investchronicle.com
On the 10th, the ADR trends show that Takeda Pharmaceutical, Nidec Corporation Sponsored ADR, Advantest, and others are performing well in terms of yen conversion. - 富途牛牛
SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow
EU approves Takeda’s new Hodgkin lymphoma treatment - Investing.com
IgA nephropathy Pipeline Drugs Analysis 2025: Clinical Trials, - openPR.com
CTVA’s Stock Market Adventure: 22.38% YTD Growth Amidst Volatility - investchronicle.com
Takeda files executive compensation report with SEC - Investing.com
Takeda schedules annual shareholder meeting - Investing.com
Cameco Earns Relative Strength Rating Upgrade; Hits Key Threshold - inkl
TD Cowen maintains Buy on Takeda, reiterates $16 target - Investing.com
Stocks With Rising Relative Strength: Novartis ADR - inkl
Fidelity Natl Info Svcs Shows Rising Relative Strength; Still Shy Of Key Benchmark - inkl
Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):